Takeda strikes $1B RNAi deal with Arrowhead Pharmaceuticals

AATLD, alpha-1 antitrypsin-associated liver disease, ARO-AAT, Arrowhead Pharmaceuticals, BioPharma, biopharma nl, Californai, Daily, Japan, Osaka, Pasadena, SYN, Takeda Pharmaceutical Company, Top Story / October 8, 2020

The companies will partner on development and commercialization of ARO-AAT, Arrowhead’s Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda’s position in the AAT-augmentation therapy market.